olaparib
astrazeneca
['gyn', 'ovarian', 'solo1', 'olaparib']
after 7 years of follow-up, results from the phase 3 solo1/gog-3004 trial support maintenance olaparib to achieve long-term remission in women with newly diagnosed advanced ovarian cancer. #gyncsm #esmo22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.